medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 2

<< Back Next >>

Ann Hepatol 2013; 12 (2)

Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease

Diaz-Sanchez A, Matilla A, Nuñez Ó, Rincon D, Lorente R, Iacono OL, Merino B, Hernando A, Campos R, Clemente G, Bañares R

Language: English
References: 35
Page: 236-247
PDF size: 216.71 Kb.


ABSTRACT

Background. VCAM-1 (soluble vascular cell adhesion molecule-1) plays a role in liver angiogenesis. Hepatocellular carcinoma (HCC) has important angiogenic activity, so expression of VCAM-1 may be pathogenic. Aim. To assess the association between serum VCAM-1 (sVCAM-1) levels and features of tumour and liver disease in patients with and without HCC, and to study the influence of HCC treatment on sVCAM-1 levels. Material and methods. Concentrations in peripheral (sVCAM-1-P) and hepatic (sVCAM-1-H) veins were analysed using ELISA in 134 consecutive patients with chronic liver disease between May 2004 and February 2006, who underwent a splanchnic haemodynamic study. Of these patients, 58 had HCC. Results. sVCAM-1-P and sVCAM-1-H were well correlated in both groups. No association was found between sVCAM-1-H and tumour features. No differences were observed in sVCAM-1-H between HCC and non-HCC cirrhotic patients. There was a significant linear association between Child-Pugh stage and sVCAM-1-H in HCC-patients (Child-Pugh A [2,485 ± 1,294 ng/mL] vs. Child-Pugh B [3,408 ± 1,338 ng/mL] vs. Child-Pugh C [4,096 ± 862 ng/ mL]; p = 0.007). Seven non-cirrhotic HCC patients had a significantly lower sVCAM-1-H than cirrhotic HCC patients. Treatment of HCC leads to an increase in sVCAM-1-H levels although this was not associated with the necrosis response to treatment. Conclusions. sVCAM-1 levels are more closely associated with the severity of underlying liver disease than with the presence of HCC. sVCAM-1 levels are not associated with tumour features or invasiveness; therefore, sVCAM-1 does not seem to play an important role in the angiogenic processes of HCC.


REFERENCES

  1. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are presented in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.

  2. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203-11.

  3. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, et al. Serum soluble vascular cell adhesion molecule- 1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000; 92: 1329-36.

  4. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517-9.

  5. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Sekara E, Michail P, Rosenberg T, et al. Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, vascular adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol 2003; 98: 478-85.

  6. Nakata B, Hori T, Sunami T, Ogawa Y, Yashiro M, Maeda K, Sawada T, et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2000; 6: 1175-9.

  7. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, Tsigris C. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlation with clinicopathological features, patient survival and tumor surgery. Eur J Cancer 2001; 37; 2392-7.

  8. Langley RR, Carlisle R, Ma L, Specian RD, Gerritsen ME, Granger DN. Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma. Microcirculation 2001; 8: 335-45.

  9. Chistiansen I, Sundström C, Tötterman TH. Elevated serum levels of soluble cell adhesion molecule-1 (sVCAM-1) closely reflects tumour burden in chronic B-lymphocytic leukaemia. Br J Hematol 1998; 103: 1129-37.

  10. O’Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 2002; 38: 2252-7.

  11. Pirisi M, Fabris C, Falleti E, Soardo G, Toniutto P, Vitulli D, Gonano F, et al. Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases. Dis Markers 1996; 13: 11-7.

  12. Lo Iacono O, Garcia-Monzon C, Almasio P, García-Buey L, Craxí A, Moreno-Otero R. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Aliment Pharmacol Ther 1998; 12: 1091-9.

  13. Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C, Rendón P, Macías MA, Fernández-Gutiérrez C, Díaz F, et al. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol 2005; 40: 217-24.

  14. Lo Iacono O, Rincon D, Hernando A, Ripoll C, Catalina MV, Salcedo M, Clemente G, et al. Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. Liver Int 2008; 28: 1129-35.

  15. Ho JW, Poon RT, Tong CS, Fan ST. Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2014-8.

  16. Hyodo I, Jinno K, Tanimizu M, Doi T, Nishikawa Y, Hosokawa Y, Moriwaki S. Intercellular adhesion molecule-1 release from human hepatocellular carcinoma. Cancer Detect Prev 1996; 20: 308-15.

  17. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  18. Child CG, Turcotte JC. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.

  19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  20. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.

  21. Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 2010; 30: 52-60.

  22. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient anything worth doing should be done right. Hepatology 2004; 39: 280-2.

  23. Adams DH, Burra P, Hubscher SG, Elias E, Newman W. Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology 1994; 19: 588-94.

  24. Lim AG, Jazrawi RP, Levy JH, Petroni ML, Douds AC, Maxwell JD, Northfield TC. Soluble E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in primary biliary cirrhosis. J Hepatol 1995; 22: 416-22.

  25. Yamaguchi N, Tokushige K, Haruta I, Yamahuchi K, Hayashi N. Analysis of adhesion molecules in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1999; 14: 364-9.

  26. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945-51.

  27. Fontanini G, Vignati S, Boldrini L, Chinè S, Silvestri V, Lucchi M, Mussi A, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 861-5.

  28. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996; 56: 2013-6.

  29. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brains tumors. Cancer Res 1995; 55: 1189-93.

  30. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-35.

  31. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-5.

  32. Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, Bertolini F, et al. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat 2007; 14: 133-9.

  33. Poon RTP, Lau CPY, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-6.

  34. Spahr L, Becker C, Pugin J, Majno PE, Hadengue A. Acute portal hemodynamics and cytokine changes following selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma. Med Sci Monit 2003; 9: 383-8.

  35. Shimada MJ, Kajiyama K, Hasegawa H, Gion T, Ikeda Y, Shirabe K, Takenaka K, et al. Role of adhesion molecule expression and soluble fractions in hepatic resection. Am Coll Surg 1998; 186: 534-41.




2020     |     www.medigraphic.com